TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Renalytix ( (GB:RENX) ) has issued an announcement.
Renalytix has announced a collaboration with Tempus AI to expand the availability of its kidneyintelX.dkd test within the Tempus US network of healthcare institutions. This partnership aims to enhance patient and clinician access to precision medicine testing for chronic kidney disease, particularly for patients with type 2 diabetes. The collaboration is expected to drive innovation in diagnostics and therapeutics through the integration of multi-modal data analysis, potentially improving patient management and care outcomes.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, which is commercially available in the United States.
YTD Price Performance: -45.58%
Average Trading Volume: 124,149
Technical Sentiment Signal: Sell
Current Market Cap: £19.38M
For an in-depth examination of RENX stock, go to TipRanks’ Overview page.